Is Owkin profitable in 2026?

Owkin has not disclosed profitability figures. It reports vendor-claimed total funding of about $300M as of January 12, 2026, and signed multi-year K Pro licensing deals with AstraZeneca (May 13, 2026) and Sanofi (June 5, 2026), but no public profit or loss numbers exist.

Who are Owkin's biggest competitors?

Owkin competes with Isomorphic Labs (DeepMind spinout), Tempus AI, Recursion Pharmaceuticals, PathAI and Insitro in AI-driven drug discovery and biomarker research. As of July 2026 none has publicly taken an Owkin pharma customer.

Could AI replace Owkin?

Unlikely soon. Owkin's moat is its federated-learning network of 800+ hospitals built over a decade, per its own January 12, 2026 statement, not just its models. It now runs AI agents atop Anthropic's Claude and NVIDIA's Nemotron rather than competing purely on model quality.

Is Owkin a safe company to join in 2026?

Mixed picture. Owkin signed major pharma licenses with AstraZeneca (May 13, 2026) and Sanofi (June 5, 2026), but headcount fell to 402 by December 2025, down 15.1% year over year, partly reflecting spin-outs like Waiv and Bioptimus.

Owkin is privately held and venture-backed, valued at roughly $1 billion since becoming a 'unicorn' via a $180 million Sanofi equity investment announced May 21, 2024. Investors include Sanofi, Bpifrance, Cathay Innovation, GV and Eight Roads Ventures.

What is Owkin's K Pro product?

K Pro is Owkin's flagship 'AI Scientist' platform that orchestrates AI agents across pharma R&D decisions using its proprietary patient data network. It is licensed multi-year to AstraZeneca (May 13, 2026) and Sanofi (June 5, 2026).

AI companies and labs · France

Owkin

owkin.com ↗

Owkin runs an AI platform on hospital patient data to find drug biomarkers for pharma companies.

Protection under test

Assessed 21 July 2026 · Evidence as of 21 July 2026

Something worth protecting exists and is being tested right now.

On the recordSince 21 July 2026 · Checkable from 2027 · Every call on the record Checkpoint: Sanofi and AstraZeneca K Pro license renewal or expansion decisions

The call

Owkin has real pharma deals and a hard-to-replicate data network, but a flat valuation for four years and unverified revenue leave open whether it's growing or just surviving.

Owkin built a network connecting over 800 hospitals to help drug companies use patient data and AI to discover new medicines faster. The company is hard to replace because it took a decade to build trust with hospitals and it stays neutral between competing drug makers, but other companies like Isomorphic Labs (backed by DeepMind) and Tempus are chasing the same customers, and giant tech companies like Google and NVIDIA could build their own drug discovery tools. The biggest test is whether the two big drug companies now paying Owkin, AstraZeneca and Sanofi, actually keep buying and expanding those deals, or if they were just testing the idea.

Why

AI pressure: Isomorphic Labs. DeepMind's drug-discovery spinout has AlphaFold-class models and its own pharma deals, hunting the same licenses Owkin sells. Could AI do the core job? Only partly.

Bigger players: IQVIA/Datavant. These neutral data brokers already sit inside hospital data flows and could build a competing AI layer, but haven't yet. Could a giant copy it? Probably.

What protects it. A decade of hospital relationships and federated-learning trust that new entrants can't buy or copy quickly.

What would change this call

Whether Sanofi or AstraZeneca renews or expands K Pro licenses at contract term. Shows if pharma partnerships are durable revenue or short-term pilots.
Whether Isomorphic Labs or Tempus signs a multi-year pharma deal in pathology or biomarker decision support. Would show a named rival capturing Owkin's core wedge.
Whether Owkin raises a new funding round at a valuation above roughly $1 billion. Would show investor confidence resuming after four flat years.

Key numbers

Valuation flat near $1B since 2022 (2022)
Headcount fell ~15% in 2025 (468 to 402) (2025)
Revenue estimates range $75M to $125M ARR (2026)

Named risks

Platform dependency on Anthropic and NVIDIA foundation models for core AI capability. Severity: high
Valuation flat near $1B since 2022 despite record AI funding environment. Severity: medium
Headcount fell 15.1% year over year to 402 by December 2025 per third-party tracker. Severity: medium
Crowded competitive field including Isomorphic Labs, Tempus, Recursion, PathAI, Insitro. Severity: medium
No disclosed marketed drug or clinically validated biomarker attributable to Owkin as of July 2026. Severity: high

Rivals, as read in July 2026

Rival	Direction	Evidence
Isomorphic Labs	contesting	DeepMind spinout with AlphaFold3-class capability, no confirmed pharma logo loss from Owkin as of 2026
Tempus AI	contesting	Comparably resourced precision-medicine peer competing for same pharma R&D deals
Recursion Pharmaceuticals	contesting	Own data collaboration with Tempus announced Nov 9, 2023, expanding rival data access
IQVIA and Datavant	contesting	Neutral data incumbents capable of building a competing agent layer but have not done so as of 2026
Anthropic and NVIDIA	gaining on	Frontier labs entering biology directly via Claude for Healthcare (Jan 12, 2026) and Nemotron, potential future rivals despite current partnership

Questions people ask

Is Owkin profitable in 2026?: Owkin has not disclosed profitability figures. It reports vendor-claimed total funding of about $300M as of January 12, 2026, and signed multi-year K Pro licensing deals with AstraZeneca (May 13, 2026) and Sanofi (June 5, 2026), but no public profit or loss numbers exist.
Who are Owkin's biggest competitors?: Owkin competes with Isomorphic Labs (DeepMind spinout), Tempus AI, Recursion Pharmaceuticals, PathAI and Insitro in AI-driven drug discovery and biomarker research. As of July 2026 none has publicly taken an Owkin pharma customer.
Could AI replace Owkin?: Unlikely soon. Owkin's moat is its federated-learning network of 800+ hospitals built over a decade, per its own January 12, 2026 statement, not just its models. It now runs AI agents atop Anthropic's Claude and NVIDIA's Nemotron rather than competing purely on model quality.
Is Owkin a safe company to join in 2026?: Mixed picture. Owkin signed major pharma licenses with AstraZeneca (May 13, 2026) and Sanofi (June 5, 2026), but headcount fell to 402 by December 2025, down 15.1% year over year, partly reflecting spin-outs like Waiv and Bioptimus.
Who owns Owkin?: Owkin is privately held and venture-backed, valued at roughly $1 billion since becoming a 'unicorn' via a $180 million Sanofi equity investment announced May 21, 2024. Investors include Sanofi, Bpifrance, Cathay Innovation, GV and Eight Roads Ventures.
What is Owkin's K Pro product?: K Pro is Owkin's flagship 'AI Scientist' platform that orchestrates AI agents across pharma R&D decisions using its proprietary patient data network. It is licensed multi-year to AstraZeneca (May 13, 2026) and Sanofi (June 5, 2026).

Timeline

2026-06-05Multi-year K Pro collaboration with Sanofi announced
2026-06-05Waiv spin-out, formerly Owkin Dx, launched with $33M financing
2026-05-13Three-year K Pro license agreement signed with AstraZeneca
2026-02-18Partnerships with India's Omics Bank and 4baseCare announced
2026-01-14NVIDIA collaboration to enhance OwkinZero using Nemotron, NeMo
2026-01-12Agentic biology infrastructure and Anthropic Claude integration launched at JPM Healthcare
2024-05-21Owkin reaches unicorn status via $180M Sanofi equity investment
2024-02Bioptimus foundation-model biology company spun out of Owkin
2016-08-03Owkin founded by Thomas Clozel and Gilles Wainrib

Revision history

21 July 2026

First assessed. Protection under test. The text above is fixed as of this date and is not edited afterwards.

In the same band

Anthropic Stability AI Darktrace